Scientists have identified an experimental drug, CADD522, originally developed for cancer treatment, that shows potential for treating bone loss and midlife weight gain. Researchers in the UK and Maryland found that the drug, when tested on postmenopausal mice, not only strengthened their bones but also led to weight loss.
Osteoporosis, a condition causing bones to weaken and increasing fracture risk, affects approximately one in five women over 50. Current treatments for osteoporosis are available but can cause significant side effects such as hot flashes, leg cramps, and swelling. Some medications require patients to remain upright for 30 minutes after administration.
The experimental drug CADD522 works by blocking a protein linked to tumor growth. In the study, published in npj Drug Discovery, mice that received the drug for eight weeks exhibited improved bone volume and better preservation of internal bone structures compared to a control group. Blood tests indicated that the drug stimulated new bone growth.
Researchers were surprised to observe that the mice treated with CADD522 also lost weight. While the exact mechanism for weight loss is unclear, scientists suggest it may indicate a potential benefit for weight management. The drug was also found to be well-tolerated in rats and dogs, and preliminary tests on human tissue showed it was broken down more slowly, potentially enhancing its effectiveness.
Dr. Darrell Green, a biomedical scientist at the University of East Anglia who led the study, stated that this discovery presents a novel approach to tackling osteoporosis. He expressed hope that the findings could pave the way for a new generation of treatments that address bone loss and metabolic changes associated with menopause.
In the United States, an estimated 10 million people have osteoporosis, and an additional 44 million have osteopenia, a precursor condition characterized by low bone density. Bone density naturally begins to decrease around age 35. Women over 50 are particularly susceptible due to hormonal fluctuations during menopause that accelerate bone loss. Factors such as being naturally thin, smoking, lack of physical activity, and regular alcohol consumption also increase the risk.
While CADD522 has shown promising results in animal models, it remains in the early stages of development and is likely years away from patient use. Researchers are optimistic that these benefits will translate to humans, potentially leading to a reduction in fracture rates.